Monensin may inhibit melanoma by regulating the selection between differentiation and stemness of melanoma stem cells.

Monensin may inhibit melanoma by regulating the selection between differentiation and stemness of melanoma stem cells.

Publication date: Feb 13, 2019

Melanoma is the most lethal cutaneous malignancy that threatens human lives. Poor sensitivity to chemotherapy drugs and the high rate of resistance are the bottlenecks of melanoma treatment. Thus, new chemotherapy drugs are needed. Drug repurposing is a safe, economical and timesaving way to explore new chemotherapy for diseases. Here, we investigated the possibility of repurposing the antibiotic monensin as an anti-melanoma agent. Using three human melanoma cells and two nomal human cell lines as cell models, we found that monensin is obviously toxic to human melanoma cells while safe to nomal human cells. It effectively inhibited cell proliferation and viability, while promoted apoptosis and differentiation of human melanoma cells in vitro. By establishment of an animal model of transplanted human melanoma in nude mice, we demonstrated that monensin suppressed the growth of xenografts in vivo. At the same time, we found that melanogenesis increased and the ability of sphere and cloning forming of melanoma decreased under the treatment of monensin. Further detection about differentiation and pluripotent regulations were executed. Our results suggest that monensin is a potent inhibitor of melanoma, and its anti-tumor mechanism may be through promoting the final differentiation of melanoma stem cells and inhibiting their stemness maintenance.

Open Access PDF

Xin, H., Li, J., Zhang, H., Li, Y., Zeng, S., Wang, Z., Zhang, Z., and Deng, F. Monensin may inhibit melanoma by regulating the selection between differentiation and stemness of melanoma stem cells. 23755. 2019 PeerJ (7):

Concepts Keywords
Antibiotic Stem cells
Apoptosis Chemotherapy
Chemotherapy Apoptosis
Cloning Cloning
Inhibitor Monensin
Malignancy Chemistry
Melanogenesis RTT
Melanoma Chemical compounds
Pluripotent Cancer
Sphere Organic compounds
Stem Cells Melanoma
Stemness Chemotherapy
Tumor Monensin toxic melanoma
Vivo Melanoma agent melanoma
Xenografts Anti tumor
Apoptosis differentiation melanoma
Final differentiation melanoma
Melanoma treatment

Semantics

Type Source Name
disease DOID Cancer
pathway BSID Melanogenesis
disease MESH growth
gene UNIPROT NDE1
pathway BSID Apoptosis
disease MESH malignancy
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *